Technion – Israel Institute of Technology Assistant Professor Assaf Zinger and Dr. Caroline Cvetkovic from the Center for Neuroregeneration at the Houston Methodist Research Institute have created a novel means of delivering medicine to neurons in a targeted manner.
The biomimetic nano-vesicles, or nature-mimicking, nanometer-scale “vehicles,” are capable of specifically targeting neurons such as nerve cells. These nano-vehicles pave the way for the treatment of multiple neurodegenerative diseases and traumatic brain injuries.
Assistant Professor Assaf Zinger
Drug delivery is a major challenge that must be overcome in drug development, and it is one of the focus areas of the Wolfson Faculty of Chemical Engineering at the Technion. It is not enough that a substance can lead to the desired therapeutic effect in a specific cell. This therapeutic substance must also reach these cells without being changed or destroyed en route, and it must not end up in other organs if it might cause harm there.
Nano-vesicles are similar in structure to human cells, but much smaller — one millionth of a hair’s width in diameter. They can carry within them cargo that needs to be delivered to the cells such as medication, mRNA, etc.
Nano-vesicles can be targeted by incorporating specific cell membrane-derived proteins on their surface, thus letting them be recognized and taken in by the correct cells. In essence, the nano vesicles (or taxis) masquerade as neurons, resulting in their being recognized and welcomed by other neurons, thereby making it possible for them to deliver their therapeutic cargo.
Neurosomes”- Humanized Biomimetic nano vesicles (red) for neuron targeting (green)
Potentially revolutionizing the treatment of neurodegenerative disorders and traumatic brain injuries
These findings have broad implications. More than one neurodegenerative disorder might be treated if the correct medicine or genetic cargo (e.g., mRNA, SiRNA, miRNA) could be delivered to the brain. But these are not the only possible applications.
“With [nano-taxis], we can also potentially revolutionize the treatment of traumatic brain injuries,” Prof. Zinger explained. “In the case of a car accident and or a sports injury, as examples, the brain is first damaged by the impact, as it is struck against the skull. As a result, multiple brain cells are damaged. This starts a process of inflammation. If we could immediately deliver anti-inflammatory drugs to the brain, we could reduce the inflammatory processes, and hopefully prevent fatalities and long-term disabilities.”
The lion’s share of this study was conducted by Prof. Zinger at the Houston Methodist Research Institute and Houston Methodist Hospital as part of his postdoctoral fellowship. Prof. Zinger recently opened a multidisciplinary laboratory at the Technion, in the Wolfson Faculty of Chemical Engineering. His lab aims to create advanced bioinspired technologies and translational therapeutics through a highly multidisciplinary approach.